Anthem Biosciences IPO GMP Today: Final Day Bidding, Subscription, Allotment, and Market Sentiment
Anthem Biosciences IPO bidding ends today with strong market interest. Explore its GMP trends, subscription data, listing expectations, and key investor insights.
Table of Contents
Introduction
Anthem Biosciences, one of India’s prominent Contract Research and Manufacturing Services (CRAMS) companies, has garnered significant investor attention as its IPO enters the final day of bidding today, July 16, 2025. With a robust grey market premium (GMP) and solid fundamentals backing the issue, analysts expect enthusiastic retail and institutional participation.
H1: What is Anthem Biosciences?
H2: Company Profile and Business Strength
Founded in 2007, Anthem Biosciences Limited is headquartered in Bangalore and has emerged as a key player in the biopharmaceutical and biotechnology contract research and manufacturing space. Its offerings include:
Contract manufacturing of intermediates and active pharmaceutical ingredients (APIs)
Development and scale-up services for biotech companies globally
Strong R&D pipeline supported by state-of-the-art facilities
The company’s diversified client base across North America, Europe, and Asia ensures revenue stability, making it an attractive investment option.
H1: Anthem Biosciences IPO Details
H2: Issue Size, Price Band, and Lot Size
IPO Size: ₹1,500 crore (approx)
Price Band: ₹410 – ₹440 per share
Lot Size: 34 shares per lot
The IPO aims to raise funds for debt repayment, facility expansion, and general corporate purposes.
H2: Subscription Status as of Day 3
As per updated data on July 16, 2025 (final bidding day):
Overall Subscription: ~15.6 times
Qualified Institutional Buyers (QIB): 22.3 times
Non-Institutional Investors (NII): 18.1 times
Retail Individual Investors (RII): 7.9 times
This reflects strong institutional backing and confident retail investor interest.
H1: Anthem Biosciences GMP Today
H2: Grey Market Premium Analysis
As of today:
GMP: ₹155-₹165 per share
Expected Listing Price: Around ₹600, indicating a ~35-40% listing gain over the upper band.
Analysts caution that while GMP is an unofficial indicator, it reflects prevailing market sentiment about the IPO’s potential.
H2: Factors Influencing High GMP
Strong growth in the global CRAMS market
Robust R&D and biotech contract pipeline
Attractive pricing relative to peers
Proven management and operational efficiency
H1: Allotment, Listing Date, and Refunds
H2: Key Dates
IPO Close Date: July 16, 2025
Allotment Finalisation: Likely by July 19, 2025
Refund Initiation: July 21, 2025
Shares Credited to Demat: July 22, 2025
Expected Listing Date: July 23, 2025 (NSE & BSE)
Investors can check their allotment status on the registrar’s website once declared.
H1: Should You Invest?
H2: Analyst Recommendations
Most brokerage houses have rated Anthem Biosciences IPO as ‘Subscribe’, citing:
Leadership in biotech and API contract manufacturing
Healthy financial growth with an improving EBITDA margin
Increasing global biotech outsourcing trend
However, investors should also consider broader market volatility, sectoral risks, and personal portfolio diversification before subscribing.
FAQ
Q1. What is Anthem Biosciences GMP today?
The GMP is ₹155-₹165 per share, indicating a potential 35-40% listing gain.
Q2. When will Anthem Biosciences IPO allotment be finalised?
Tentatively by July 19, 2025.
Q3. What is the IPO price band and lot size?
Price band is ₹410-₹440 per share with a lot size of 34 shares.
Q4. What is the listing date for Anthem Biosciences IPO?
Expected listing on July 23, 2025 on NSE and BSE.
Helpful Resources
Conclusion
Anthem Biosciences IPO has captured investor attention due to its leadership position in the CRAMS industry, strong financials, and promising market outlook. While its GMP suggests significant listing gains, investors should evaluate their risk appetite and sector exposure before subscribing.
Post Comment